Spontaneously reported haemorrhagic adverse events associated with rivaroxaban and dabigatran in Australia

Conclusions:
Our study highlights the need for research on the haemorrhagic complications of anticoagulation in clinical care. A considerable proportion of reported haemorrhagic events occurred within 30 days of rivaroxaban and dabigatran initiation. This highlights the importance of considering bleeding risk at the time of treatment initiation.

Source: Therapeutic Advances in Drug Safety - January 15, 2016 Category: Drugs & Pharmacology Authors: Chen, E. Y. H., Diug, B., Bell, J. S., Mc Namara, K. P., Dooley, M. J., Kirkpatrick, C. M., McNeil, J. J., Caughey, G. E., Ilomäki, J. Tags: Original Research Source Type: research